In connection with the implementation by the Ordering Party of the project entitled “Use of matrix metalloproteinase inhibitor to develop an innovative therapy of preventing the development of post-traumatic and post-stroke epilepsy” /POIR.01.01.01-00-0235/20-00/ within Measure 1.1. R&D projects of enterprises, Submeasure 1.1.1 Industrial research and development work implemented by enterprises, co-financed by the European Regional Development Fund, and also in connection with the obligation to apply the principle of competitiveness, Pikralida sp. z o. o. invites you to submit offers for expert consulting services related to drug development and regulatory affairs, and preparation of regulatory documents.
In connection with occurring questions of the subject matter of the order from the bidders, we inform you that the deadline for concluding the offer has been extended until August 26, until: 11:59 pm.
Bids should be submitted electronically to the following e-mail address: pricing_offers@pikralida.eu or via the competitiveness database (link below), in person, by post or by courier to the address of our registered office (date of receipt shall be considered) by the August 26, 2022, until: 11:59 pm.
The request for proposal No. 63/2022 and template documents have been published in the Competitiveness Database:
https://bazakonkurencyjnosci.funduszeeuropejskie.gov.pl/ogloszenia/121435